Table 1 Demographic data of included patients, on first baseline visit, who underwent in-office vocal fold injections of hyaluronic acid between August 2017 to December 2019 (n = 136)
From: Do patients regret having in-office vocal fold injections for glottic insufficiency?
Variable | Data |
|---|---|
Gender, n (%) | |
Female | 57 (41.9%) |
Male | 79 (58.1%) |
Diagnosis, n (%) | |
Paralysis | 71 (52.2%) |
Paresis | 33 (24.3%) |
Presbyphonia | 32 (23.5%) |
Etiology, n (%) | |
Iatrogenic | 55 (40.4%) |
Idiopathic | 50 (36.8%) |
Malignant | 17 (12.5%) |
Neurological | 7 (5.2%) |
Other | 7 (5.2%) |
Side of vocal fold pathology, n (%) | |
Left | 71 (52.2%) |
Right | 30 (22.1%) |
Bilateral | 35 (25.7%) |
Professional voice user, n (%) | |
Yes | 29 (21.3%) |
No | 107 (78.7%) |
Age (years) | |
Mean (SD) | 65.4 (13.9) |
Duration of hoarseness (months) | |
Mean (SD) | 15.5 (30.7) |
BMI | |
Mean (SD) | 26.2 (7.7) |
Voice Handicap Index-10 (baseline) | |
Mean (SD) | 24.0 (9.1) |
GRBAS–Grade on baseline visit | |
0 | 0.8% |
1 | 16% |
2 | 47.2% |
3 | 36% |
Maximum Phonation Time (seconds) | |
Mean (SD) | 7.20 (5.47) |
Subsequent thyroplasty, n (%) | 16 (11.8%) |
Time from in-office vocal fold injection to survey administration (months) | |
Mean (SD), range | 20,1 (8.1), 8.3–35.7 |